Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data
Received Date : 14 Feb 2024
Accepted Date : 23 May 2024
Available Online : 04 Jun 2024
Goncagül AKDAĞa, Özkan ALANb, Akif DOĞANa, Sedat YILDIRIMa, Oğuzcan KINIKOĞLUa,
Nargiz MAJIDOVAc, İbrahim Vedat BAYOĞLUc, Caner KAPARd, Eda ERÇİNe,
Zeynep ALACA TOPÇUf, Murad GULIYEVg, Deniz IŞIKa, Özlem Nuray SEVERa,
Hatice ODABAŞa, Mahmut Emre YILDIRIMa, Nedim TURANa
aUniversity of Health Science Kartal Dr. Lütfi Kırdar City Hospital, Division of Medical Oncology, İstanbul, Türkiye
bKoç University Faculty of Medicine, Division of Medical Oncology, İstanbul, Türkiye
cMarmara University Pendik Training and Research Hospital, Division of Medical Oncology, İstanbul, Türkiye
dBakırköy Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Türkiye
eÜmraniye Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Türkiye
fMedeniyet University Faculty of Medicine, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Division of Medical Oncology, İstanbul, Türkiye
gİstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Division of Medical Oncology, İstanbul, Türkiye
Doi: 10.37047/jos.2024-102164 - Article's Language: EN
J Oncol Sci.
ABSTRACT
Objective: Patients with metastatic breast cancer (MBC) with a history of treatment with anthracyclines and taxanes exhibit improvement
with ixabepilone, a semi-synthetic analog of epothilone B. The present study, therefore, aimed to evaluate the safety and effectiveness
of ixabepilone in patients with MBC who have previously received multiple lines of treatment Material and Methods: Patients with MBC
who were treated with ixabepilone were included in the present study, which was designed as a retrospective multicenter analysis. Radiological
responses were evaluated based on the RECIST criteria, and overall survival (OS) and progression-free survival (PFS) were calculated. The Common
Terminology Criteria for Adverse Events version 5.0 was adopted to evaluate adverse events. Results: The analysis of 34 patients revealed
a median OS of 10.0 months, a median PFS of 4.2 months, and an objective response rate (ORR) of 28%.The patients treated with ixabepilone
prior to the fifth line of treatment exhibited a significantly better response (ORR 50%). In the subgroup analysis based on receptor status, ER+
and human epidermal growth factor receptor-2 (HER2+) patients presented the longest median PFS of 6.2 months. Conclusion: Ixabepilone
demonstrated effectiveness in patients with MBC who had received multiple lines of treatments previously. The results suggest that early treatment
regimens or targeted therapy for HER2+ patients could lead to better therapeutic outcomes when ixabepilone is administered. Ixabepilone
is, therefore, a viable option for MBC patients who have received extensive treatment previously while maintaining a good performance status.
Keywords: Ixabepilone; metastatic breast cancer; overall survival; progression-free survival